secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0000950170-24-024878
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics closes $632.5M public offering of 7.44M shares at $85.00
----------------------------------------------------------------------------

- Closed public offering of 7,441,650 shares at $85.00 each, including full exercise of underwriters' option for 970,650 additional shares.
- Gross proceeds of approximately $632.5 million before underwriting discounts and offering expenses.
- Net proceeds will fund continued development of VK2809, VK2735, VK0214 programs and general corporate purposes.
- Joint book-running managers: Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel, Truist Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024024878/0000950170-24-024878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024024878/vktx-20240304.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-024878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer